| 2012 | | Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B | 김순선, 이명희, 정재연, 조성원 |
| 1998 | | Augmented eradication rates of Helicobacter pylori by new combination therapy with lansoprazole, amoxicillin, and rebamipide. | 김영수, 김진홍, 이광재, 임현이, 조성원, 주희재, 함기백 |
| 2015 | | Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial. | 이광재 |
| 2017 | | Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies | 김대중, 이광재 |
| 2020 | | Impact of previous metronidazole exposure on metronidazole-based second-line quadruple therapy for Helicobacter pylori infection | 강준구, 김진홍, 노충균, 신성재, 이기명, 이길호, 임선교 |
| 2013 | | Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population. | 정재연, 조성원 |
| 1998 | | Quantitative and qualitative usefulness of rebamipide in eradication regimen of Helicobacter pylori. | 김영수, 김진홍, 이광재, 임현이, 조성원, 주희재, 함기백 |
| 2015 | | Tenofovir-based rescue therapy in chronic hepatitis B patients with suboptimal responses to adefovir with prior lamivudine resistance. | 김순선, 신성재, 유병무, 정재연, 조성원, 조효정 |
